{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:20:01Z","timestamp":1772644801544,"version":"3.50.1"},"reference-count":109,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mark Gilbert and Karen Simmonds Research Gift Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and is responsible for the majority of cervical, anal, and vaginal cancers. The first prophylactic HPV vaccine was introduced in the United States in 2006. Extensive evidence demonstrates the HPV vaccine is highly efficacious and effective, particularly when administered prior to HPV exposure. Despite strong safety data and proven cost-effectiveness, HPV vaccine uptake in the United States and globally remains suboptimal. Barriers to vaccination include limited knowledge, safety concerns, and logistical challenges. Current advancements focus on single-dose vaccine regimens, development of therapeutic vaccines, and higher-valent formulations. Expanding HPV vaccine coverage is essential to reduce HPV-related diseases, strengthen herd immunity, and advance cancer prevention efforts.<\/jats:p>","DOI":"10.3390\/vaccines14030236","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:11:36Z","timestamp":1772629896000},"page":"236","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Pocket Manual for Human Papillomavirus Vaccines"],"prefix":"10.3390","volume":"14","author":[{"given":"Natalie A.","family":"Voss","sequence":"first","affiliation":[{"name":"Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-135X","authenticated-orcid":false,"given":"J. Brooks","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-5746","authenticated-orcid":false,"given":"Mary B.","family":"Rysavy","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, & Reproductive Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3892\/ol.2014.2226","article-title":"The paediatric story of human papillomavirus (Review)","volume":"8","author":"Mammas","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Illah, O., and Olaitan, A. (2023). Updates on HPV Vaccination. Diagnostics, 13.","DOI":"10.3390\/diagnostics13020243"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.08.015","article-title":"The natural history of human papillomavirus infection","volume":"47","author":"Brotons","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bpobgyn.2011.05.001","article-title":"History of human papillomavirus, warts and cancer: What do we know today?","volume":"25","author":"Onon","year":"2011","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/modpathol.2015.54","article-title":"Microanatomy of the cervical and anorectal squamocolumnar junctions: A proposed model for anatomical differences in HPV-related cancer risk","volume":"28","author":"Yang","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_6","unstructured":"(2025, December 23). CDC About Genital HPV Infection Sexually Transmitted Infections (STIs), Available online: https:\/\/www.cdc.gov\/sti\/about\/about-genital-hpv-infection.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/01443615.2015.1030606","article-title":"Effect of mode of delivery on vertical human papillomavirus transmission\u2014A meta-analysis","volume":"36","author":"Chatzistamatiou","year":"2016","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMcp2108502","article-title":"Human Papillomavirus Vaccination","volume":"388","author":"Markowitz","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex. Transm. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12967-025-06470-x","article-title":"Human papilloma virus (HPV) mediated cancers: An insightful update","volume":"23","author":"Baba","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_11","unstructured":"(2026, February 16). Cancer Today. Available online: https:\/\/gco.iarc.who.int\/today\/."},{"key":"ref_12","unstructured":"(2026, February 26). Cancer (IARC) TIA for R on Global Cancer Observatory. Available online: https:\/\/gco.iarc.fr\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e29332","DOI":"10.1002\/jmv.29332","article-title":"The International Human Papillomavirus Reference Center: Standardization, collaboration, and quality assurance in HPV research and diagnostics","volume":"95","author":"Lagheden","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Miller, J.M., Binnicker, M.J., Campbell, S., Carroll, K.C., Chapin, K.C., Gonzalez, M.D., Harrington, A., Jerris, R.C., Kehl, S.C., and Leal, S.M. (2024). Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin. Infect. Dis., ciae104.","DOI":"10.1093\/cid\/ciae104"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/LGT.0000000000000865","article-title":"Applying Results of Extended Genotyping to Management of Positive Cervicovaginal Human Papillomavirus Test Results: Enduring Guidelines","volume":"29","author":"Massad","year":"2025","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Har\u0119\u017ca, D.A., Wilczy\u0144ski, J.R., and Paradowska, E. (2022). Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031818"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1476-4598-10-140","article-title":"Papillomavirus E5: The smallest oncoprotein with many functions","volume":"10","author":"Venuti","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1016\/j.vaccine.2007.01.013","article-title":"Developing an HPV vaccine to prevent cervical cancer and genital warts","volume":"25","author":"Bryan","year":"2007","journal-title":"Vaccine"},{"key":"ref_19","unstructured":"(2025, December 23). CDC Cancers Linked with HPV Each Year. Cancer, Available online: https:\/\/www.cdc.gov\/cancer\/hpv\/cases.html."},{"key":"ref_20","unstructured":"Office of Science Policy (2026, January 15). Significant Research Advances Enabled by HeLa Cells, Available online: https:\/\/osp.od.nih.gov\/hela-cells\/significant-research-advances-enabled-by-hela-cells\/."},{"key":"ref_21","unstructured":"Cowan, C., Quick, H., and Redondo, L. (2026, January 15). Celebrating the Life of Henrietta Lacks: How One Black Woman Unknowingly Changed Modern Medicine. Nsgc-Perspectives. Available online: https:\/\/perspectives.nsgc.org\/Article\/celebrating-the-life-of-henrietta-lacks."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/acsptsci.9b00032","article-title":"The HPV Vaccine Story","volume":"2","author":"Frazer","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_23","unstructured":"(2025, December 23). History of HPV Vaccines and Screening. Available online: https:\/\/sto-online.org\/harmony\/history-of-hpv-vaccines-and-screening\/."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Akg\u00f6r, U., Temiz, B.E., Cengiz, M., Ege, H.V., Joura, E., and G\u00fcltekin, M. (2026). New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review. Vaccines, 14.","DOI":"10.3390\/vaccines14020140"},{"key":"ref_25","unstructured":"CDC (2026, January 15). HPV Vaccine Safety and Effectiveness, Available online: https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv\/hcp\/safety-effectiveness.html."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.vaccine.2020.11.076","article-title":"Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence","volume":"39","author":"Brown","year":"2021","journal-title":"Vaccine"},{"key":"ref_27","unstructured":"(2025, December 23). WHO Updates Recommendations on HPV Vaccination Schedule. Available online: https:\/\/www.who.int\/news\/item\/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule."},{"key":"ref_28","unstructured":"CDC HPV Vaccination (2025, December 14). Human Papillomavirus (HPV), Available online: https:\/\/www.cdc.gov\/hpv\/vaccines\/index.html."},{"key":"ref_29","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Adolescent Health Care, and American College of Obstetricians and Gynecologists\u2019 Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group (2020). Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809. Obstet. Gynecol., 136, e15."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet Lond. Engl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Practice Committee of the American Society for Reproductive Medicine (2024). Current recommendations for vaccines for patients planning pregnancy: A committee opinion. Fertil. Steril., 122, 62\u201367.","DOI":"10.1016\/j.fertnstert.2024.02.027"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2377903","DOI":"10.1080\/21645515.2024.2377903","article-title":"Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women","volume":"20","author":"Kjaer","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","article-title":"Efficacy of the bivalent HPV vaccine against HPV 16\/18-associated precancer: Long-term follow-up results from the Costa Rica Vaccine Trial","volume":"21","author":"Porras","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Giuliano","year":"2015","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/infdis\/jix244","article-title":"Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003\u20132014","volume":"216","author":"Oliver","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"918","DOI":"10.7326\/M21-3798","article-title":"Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018","volume":"175","author":"Rosenblum","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.15585\/mmwr.mm7012a2","article-title":"Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine\u2014United States, 2003\u20132018","volume":"70","author":"Rosenblum","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_40","first-page":"CD015363","article-title":"Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination","volume":"11","author":"Henschke","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: A register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e077341","DOI":"10.1136\/bmj-2023-077341","article-title":"Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: Population based observational study","volume":"385","author":"Falcaro","year":"2024","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/jamapediatrics.2025.3568","article-title":"Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction","volume":"179","author":"DeSieghardt","year":"2025","journal-title":"JAMA Pediatr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e20181902","DOI":"10.1542\/peds.2018-1902","article-title":"Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women","volume":"143","author":"Spinner","year":"2019","journal-title":"Pediatrics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2105\/AJPH.2017.304119","article-title":"Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006\u20132014","volume":"108","author":"Flagg","year":"2018","journal-title":"Am. J. Public Health"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/cid\/ciab171","article-title":"Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States","volume":"73","author":"Meites","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jop.70016","article-title":"HPV-Vaccine and Reduced Odds Ratio for Oral and Oropharyngeal Cancer in Both Genders","volume":"54","author":"Katz","year":"2025","journal-title":"J. Oral Pathol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/OLQ.0000000000001405","article-title":"Human Papillomavirus Vaccine to End Oropharyngeal Cancer. A Systematic Review and Meta-Analysis","volume":"48","author":"Tsentemeidou","year":"2021","journal-title":"Sex. Transm. Dis."},{"key":"ref_50","unstructured":"(2025, December 22). HPV Vaccines|Preventing Human Papillomavirus Infection. Available online: https:\/\/www.cancer.org\/cancer\/risk-prevention\/hpv\/hpv-vaccines.html."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2530831","DOI":"10.1080\/21645515.2025.2530831","article-title":"Adverse events following 9-valent human papillomavirus vaccine (GARDASIL\u00ae 9) reported to the Vaccine Adverse Event Reporting System (VAERS), 2015\u20132024","volume":"21","author":"Liu","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e20191791","DOI":"10.1542\/peds.2019-1791","article-title":"Safety of the 9-Valent Human Papillomavirus Vaccine","volume":"144","author":"Shimabukuro","year":"2019","journal-title":"Pediatrics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e20154387","DOI":"10.1542\/peds.2015-4387","article-title":"Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"key":"ref_55","unstructured":"(2025, December 22). Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices, Available online: https:\/\/www.cdc.gov\/mmwR\/preview\/mmwrhtml\/mm6411a3.htm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e20191808","DOI":"10.1542\/peds.2019-1808","article-title":"Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine","volume":"144","author":"Donahue","year":"2019","journal-title":"Pediatrics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40264-017-0625-z","article-title":"Safety of Human Papillomavirus Vaccines: An Updated Review","volume":"41","author":"Phillips","year":"2018","journal-title":"Drug Saf."},{"key":"ref_58","unstructured":"(2026, February 15). Safety. Available online: https:\/\/www.who.int\/groups\/global-advisory-committee-on-vaccine-safety\/topics\/human-papillomavirus-vaccines\/safety."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Rosettie, K.L., Joffe, J.N., Sparks, G.W., Aravkin, A., Chen, S., Compton, K., Ewald, S.B., Mathew, E.B., Michael, D., and Pedroza Velandia, P. (2021). Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260808"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.vaccine.2022.03.046","article-title":"Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis","volume":"40","author":"Tejada","year":"2022","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mahumud, R.A., Alam, K., Keramat, S.A., Ormsby, G.M., Dunn, J., and Gow, J. (2020). Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233499"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1016\/j.vaccine.2022.05.025","article-title":"The cost-effectiveness of human papillomavirus vaccination in the Philippines","volume":"40","author":"Llave","year":"2022","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1473-3099(20)30860-4","article-title":"Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: A mathematical modelling analysis","volume":"21","author":"Drolet","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.vaccine.2024.01.094","article-title":"Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review","volume":"42","author":"Slavkovsky","year":"2024","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ewongwo, A., Sahor, A.F., Ngwa, W., and Nwachukwu, C. (2024). A guide to global access to HPV vaccination to all women in low- and middle-income countries, a minireview of innovation and equity. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1380663"},{"key":"ref_66","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(14)70481-4","article-title":"Present status of human papillomavirus vaccine development and implementation","volume":"16","author":"Herrero","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_68","unstructured":"ViewHub (2025, December 23). Single-Dose HPV Vaccination. Available online: https:\/\/view-hub.org\/topics\/single-dose-hpv."},{"key":"ref_69","unstructured":"(2026, February 16). WHO Immunization Data Portal\u2014Detail Page. Immunization Data. Available online: https:\/\/immunizationdata.who.int\/global\/wiise-detail-page."},{"key":"ref_70","unstructured":"(2025, December 23). Human Papillomavirus Vaccination. Available online: https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2020\/08\/human-papillomavirus-vaccination."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_72","first-page":"274","article-title":"Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation","volume":"70","author":"Saslow","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_73","unstructured":"Greenberg, G.M., Koshy, P.A., and Hanson, M.J.S. (2026, January 15). Adult Vaccination. Available online: https:\/\/www.aafp.org\/pubs\/afp\/issues\/2022\/1100\/adult-vaccination.html."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Cassimos, D.C., Effraimidou, E., Medic, S., Konstantinidis, T., Theodoridou, M., and Maltezou, H.C. (2020). Vaccination Programs for Adults in Europe, 2019. Vaccines, 8.","DOI":"10.3390\/vaccines8010034"},{"key":"ref_75","unstructured":"Impfservice Wien (2026, February 15). HPV (Human Papillomavirus). Available online: https:\/\/impfservice.wien\/en\/hpv-human-papillomavirus\/."},{"key":"ref_76","unstructured":"(2026, February 26). Cervical Cancer Elimination Initiative. Available online: https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"The Lancet Oncology (2022). HPV vaccination in south Asia: New progress, old challenges. Lancet Oncol., 23, 1233.","DOI":"10.1016\/S1470-2045(22)00567-8"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2021039","DOI":"10.4178\/epih.e2021039","article-title":"Prevalence of high-risk HPV genotypes in sub-Saharan Africa according to HIV status: A 20-year systematic review","volume":"43","author":"Okoye","year":"2021","journal-title":"Epidemiol. Health"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12985-020-01448-1","article-title":"Molecular epidemiology of human papillomavirus among HIV infected women in developing countries: Systematic review and meta-analysis","volume":"17","author":"Bogale","year":"2020","journal-title":"Virol. J."},{"key":"ref_80","unstructured":"(2026, February 26). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/news\/update-guidelines-prevention-and-treatment-opportunistic-infections-adults-and-adolescents-8."},{"key":"ref_81","unstructured":"CDC (2026, January 24). HPV Vaccination Recommendations, Available online: https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv\/hcp\/recommendations.html."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1086\/656320","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men","volume":"202","author":"Wilkin","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/cid\/ciu238","article-title":"Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women","volume":"59","author":"Kojic","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/QAD.0000000000000597","article-title":"Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults","volume":"29","author":"Rainone","year":"2015","journal-title":"AIDS"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MOP.0000000000001441","article-title":"HPV vaccine hesitancy in the United States","volume":"37","author":"Joshi","year":"2025","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_87","first-page":"CD011895","article-title":"Improving vaccination uptake among adolescents","volume":"1","author":"Abdullahi","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamapediatrics.2013.2752","article-title":"Barriers to Human Papillomavirus Vaccination Among US Adolescents: A Systematic Review of the Literature","volume":"168","author":"Holman","year":"2014","journal-title":"JAMA Pediatr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1016\/j.vaccine.2022.03.054","article-title":"Healthcare professional\u2019s promotional strategies in improving Human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review","volume":"40","author":"Markey","year":"2022","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/07853890.2018.1426875","article-title":"On surmounting the barriers to HPV vaccination: We can do better","volume":"50","author":"Attia","year":"2018","journal-title":"Ann. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ypmed.2018.05.021","article-title":"The challenge of HPV vaccination uptake and opportunities for solutions: Lessons learned from Alabama","volume":"113","author":"Dilley","year":"2018","journal-title":"Prev. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"127359","DOI":"10.1016\/j.vaccine.2025.127359","article-title":"Effective strategies in human papillomavirus (HPV) vaccination interventions to increase uptake in rural, low socioeconomic, indigenous and migrant populations: A scoping review","volume":"61","author":"Roux","year":"2025","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2468-2667(25)00148-3","article-title":"Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: A systematic review and meta-analysis","volume":"10","author":"Iwami","year":"2025","journal-title":"Lancet Public Health"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2023.4932","article-title":"Multilevel Implementation Strategies for Adolescent Human Papillomavirus Vaccine Uptake: A Cluster Randomized Clinical Trial","volume":"178","author":"Griffin","year":"2024","journal-title":"JAMA Pediatr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapediatrics.2015.0310","article-title":"Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage","volume":"169","author":"Niccolai","year":"2015","journal-title":"JAMA Pediatr."},{"key":"ref_96","unstructured":"(2026, January 15). One-Dose Human Papillomavirus (HPV) Vaccine Offers Solid Protection Against Cervical Cancer. Available online: https:\/\/www.who.int\/news\/item\/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1056\/NEJMoa2506765","article-title":"Noninferiority of One HPV Vaccine Dose to Two Doses","volume":"393","author":"Kreimer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S1470-2045(22)00543-5","article-title":"Evidence-based impact projections of single-dose human papillomavirus vaccination in India: A modelling study","volume":"23","author":"Man","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): An open-label, randomised, non-inferiority trial","volume":"10","author":"Changalucha","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): An immunobridging analysis of randomised controlled trials","volume":"12","author":"Baisley","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_102","unstructured":"(2026, January 24). Decision Memo Adopting Revised Childhood Adolescent Immunization Schedule, Available online: https:\/\/www.hhs.gov\/sites\/default\/files\/decision-memo-adopting-revised-childhood-adolescent-immunization-schedule.pdf."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jncimonographs\/lgae026","article-title":"Human papillomavirus prophylactic vaccines: Update on new vaccine development and implications for single-dose policy","volume":"2024","author":"Schuind","year":"2024","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jncimonographs\/lgae037","article-title":"Evaluating potential program cost savings with a single-dose HPV vaccination schedule: A modeling study","volume":"2024","author":"Slavkovsky","year":"2024","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Zheng, Q., He, M., Mao, Z., Huang, Y., Li, X., Long, L., Guo, M., Zou, D., Zheng, Q., and He, M. (2025). Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13010092"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"984","DOI":"10.12932\/AP-171225-2190","article-title":"Recurrent respiratory papillomatosis: Recent advances in HPV-6\/HPV-11\u2013targeted immunotherapy","volume":"43","author":"Samuckkeethum","year":"2025","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_107","unstructured":"(2026, February 16). FDA Approves Novel Tx for Rare RRP\u2014Papzimeos\u2014Anton Health. Available online: https:\/\/antonhealth.com\/fda-approves-novel-tx-for-rare-rrp-papzimeos\/."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Cheng, L., Wang, Y., and Du, J. (2020). Human Papillomavirus Vaccines: An Updated Review. Vaccines, 8.","DOI":"10.3390\/vaccines8030391"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Wang, R., Huang, H., Yu, C., Li, X., Wang, Y., and Xie, L. (2024). Current status and future directions for the development of human papillomavirus vaccines. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1362770"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/236\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:39:17Z","timestamp":1772631557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":109,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["vaccines14030236"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14030236","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}